Shares of Protagonist Therapeutics (NASDAQ: PTGX), a clinical-stage biotechnology company, are plummeting today. As of 2:26 p.m. EDT, the stock price has fallen 62.9% in response to news of a clinical hold from the FDA. Protagonist Therapeutics is advancing an ambitious pipeline with five new drug candidates in clinical trials right now.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting